Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Femasys Inc. (NASDAQ: FEMY) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As an emerging growth company and smaller reporting company, Femasys files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events affecting its business, capital structure and listing status.
Through these filings, investors can review detailed information about Femasys’ women’s health portfolio, including fertility products such as FemaSeed Intratubal Insemination and FemVue, and the FemBloc permanent birth control system. Current reports on Form 8-K have described milestones like FDA 510(k) clearance for the FemVue Controlled diagnostic device, IDE approval to advance the final phase of the FINALE pivotal trial for FemBloc, and international regulatory approvals for FemBloc in Europe and the UK. Other 8-K filings outline financing transactions, including senior secured convertible notes and associated warrants, as well as underwritten equity offerings.
Femasys’ filings also disclose its Nasdaq Capital Market listing under the symbol FEMY, notices related to continued listing requirements, and responses such as capital raises or bid-price compliance plans. Registration statements on Form S-1 and S-1/A provide further detail on offered securities, use of proceeds, risk factors and forward-looking statements related to the company’s fertility and permanent birth control strategy.
On Stock Titan, these FEMY filings are updated in real time from EDGAR and paired with AI-powered summaries that highlight key points in lengthy documents. Users can quickly locate 10-K and 10-Q reports, 8-K event disclosures, registration statements and other filings, and use AI-generated explanations to understand complex sections on clinical development, regulatory pathways, financing terms and Nasdaq compliance without reading every page.
Femasys Inc. is soliciting stockholder votes at a Special Meeting on April 29, 2026 to consider three proposals: (1) authorize a board‑discretion reverse stock split of common stock at a ratio between 1‑for‑2 and 1‑for‑25 to be set by the board prior to May 1, 2027; (2) approve potential issuances of shares upon conversion of senior secured convertible notes and exercise of multiple warrant series to the extent anti‑dilution or price adjustments reduce effective prices below the Nasdaq Minimum Price; and (3) authorize adjournment to solicit additional proxies if needed.
Only holders of record as of March 27, 2026 may vote. Shares outstanding were 60,390,686 as of that record date and total authorized common shares are 200,000,000. The board recommends a vote FOR all three proposals.
Femasys Inc. director Kenneth D. Eichenbaum filed an initial ownership report showing a mix of common stock and convertible securities. He holds 25,010 shares of common stock directly, plus senior secured convertible notes initially convertible at $0.73 per share into up to 102,366 shares.
He also holds Series A-1, B-1 and C-1 warrants, each series initially exercisable into up to 102,366 common shares at exercise prices of $0.81, $0.92, and $1.10 per share, respectively, with stated expiration in 2035. A footnote indicates the reported securities were purchased for an aggregate of $75,000.
Femasys Inc. director Kenneth D. Eichenbaum received a grant of stock options covering 35,200 shares of Common Stock. The options have an exercise price of $0.6000 per share and expire on March 18, 2036. This is a compensation-related award, not an open-market purchase or sale.
The award was reported as a direct holding. According to the footnote, the shares underlying the option will vest in annual one-third increments over a three-year period beginning on March 18, 2027, contingent on continued service. Following this grant, Eichenbaum holds 35,200 derivative securities of this type.
Femasys Inc. entered into an Omnibus Amendment and Consent Agreement with requisite note and warrant holders to remove the Share Combination Event Adjustment from its senior secured convertible notes and related warrants, effective December 31, 2025. As consideration, the company is issuing an aggregate 16,378,563 unregistered Series D-1 warrants, each exercisable at $0.58 per share, to accredited investors in a private offering under Section 4(a)(2) of the Securities Act.
The Series D-1 warrants give holders the right to acquire the same number of common shares as under their existing Series A-1 warrants. Separately, director Joshua Silverman resigned, stating his decision was not due to any dispute or disagreement with the company. The Board appointed Kenneth D. Eichenbaum, M.D., M.S.E. as a new independent Class II director under a nomination right held by Pointillist Global Macro Series of Pointillist Partners LLC, with his term running to the 2026 annual meeting.
Femasys Inc director reports no new trades. This Form 4 filing lists Joshua Silverman as a director of Femasys Inc but shows no reported transactions in company securities. The transaction summary indicates zero buys, sells, exercises, gifts, or other dispositions, reflecting neutral net trading activity for this period.
PharmaCyte Biotech, Inc. reports beneficial ownership of 4,932,825 shares of Femasys Inc. common stock, representing 7.87% of the class based on 58,479,824 shares outstanding as of November 13, 2025.
The filing states the position includes 695,537 currently held shares and Series A warrants exercisable for 4,237,288 shares (subject to a 19.99% beneficial ownership limitation); percentage was calculated using the issuer's reported outstanding shares plus the warrants.
Lee-Sepsick Kathy reported acquisition or exercise transactions in this Form 4 filing.
Femasys Inc. reported new equity awards to its CEO, Kathy Lee-Sepsick. On February 19, 2026, she received two grants totaling 729,000 restricted stock units, each representing one share of common stock. One 447,000-unit grant vests in four equal annual installments beginning February 19, 2027, while a 282,000-unit grant fully vests on February 19, 2027, in each case contingent on continued employment.
Femasys Inc. Chief Financial Officer Dov Elefant reported awards of restricted stock units (RSUs) that give him the right to acquire FEMY common shares in the future. He received 173,000 RSUs and 169,000 RSUs, each representing one share when vested. One grant vests in four equal annual installments beginning on February 19, 2027, while the other fully vests on February 19, 2027, in each case contingent on continued employment with the company or a subsidiary on the applicable vesting dates.
Sipos Jeremy Alexander reported acquisition or exercise transactions in this Form 4 filing.
Femasys Inc. Chief Technology Officer Jeremy Alexander Sipos reported an award of 80,000 restricted stock units (RSUs) on February 2, 2026. Each RSU represents a contingent right to receive one share of Femasys (FEMY) common stock.
The 80,000 RSUs were granted at a price of $0 per unit and are held as direct beneficial ownership. The RSUs vest in four equal annual installments beginning on February 2, 2027, as long as Sipos remains employed by Femasys or one of its subsidiaries on each vesting date.
Femasys Inc. Chief Technology Officer Jeremy Alexander Sipos filed an initial statement of beneficial ownership of company securities. He directly holds 46,278 shares of Femasys common stock. In addition, he reports several employee stock options to buy common stock.
The options cover different grants with exercise prices ranging from $0.80 to $6.12 per share and expiration dates between June 30, 2027 and January 28, 2035. Some grants are fully vested, while others vest in equal installments over three or four years beginning on dates in 2023, 2024, and 2025.